Your browser doesn't support javascript.
loading
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries.
Appel, Tobias Manuel; Mojica, María Fernanda; De La Cadena, Elsa; Pallares, Christian José; Radice, Marcela A; Castañeda-Méndez, Paulo; Jaime-Villalón, Diego A; Gales, Ana C; Munita, José M; Villegas, María Virginia.
Afiliação
  • Appel TM; Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia.
  • Mojica MF; Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia.
  • De La Cadena E; Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia.
  • Pallares CJ; Grupo de Resistencia Bacteriana, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali 760031, Colombia.
  • Radice MA; Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia.
  • Castañeda-Méndez P; Grupo de Resistencia Bacteriana, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali 760031, Colombia.
  • Jaime-Villalón DA; Comité de Infecciones y Vigilancia Epidemiológica, Centro Médico Imbanaco, Cali 760043, Colombia.
  • Gales AC; Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Microbiología, Universidad de Buenos Aires-CONICET, Buenos Aires C1113AAD, Argentina.
  • Munita JM; Department of Infectious Diseases, Hospital Médica Sur, Ciudad de México 14050, Mexico.
  • Villegas MV; Department of Infectious Diseases, Hospital San Angel Inn Universidad, Ciudad de México 03330, Mexico.
Antibiotics (Basel) ; 9(2)2020 Feb 05.
Article em En | MEDLINE | ID: mdl-32033394
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-ß-lactam ß-lactamase inhibitor, which has shown activity against isolates producing class A, C and D ß-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Antibiotics (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Antibiotics (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Suíça